These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
459 related articles for article (PubMed ID: 6616449)
1. Extraction of immunogenic and suppressogenic antigens from variants of B16 melanoma exhibiting low or high metastatic potentials. LeGrue SJ; Hearn DR Cancer Res; 1983 Nov; 43(11):5106-11. PubMed ID: 6616449 [TBL] [Abstract][Full Text] [Related]
2. Suppression of B16 melanoma lung colonization by syngeneic monoclonal antibodies. Herd ZL Cancer Res; 1987 May; 47(10):2696-703. PubMed ID: 3552203 [TBL] [Abstract][Full Text] [Related]
3. Expression of tumor antigen correlated with metastatic potential of Lewis lung carcinoma and B16 melanoma clones in mice. Falcioni R; Kennel SJ; Giacomini P; Zupi G; Sacchi A Cancer Res; 1986 Nov; 46(11):5772-8. PubMed ID: 3756921 [TBL] [Abstract][Full Text] [Related]
4. Multiple antigens related to the major envelope glycoprotein of murine leukemia virus expressed on B16 melanoma cells as targets of host immune response. Stackpole CW; Demsey A Invasion Metastasis; 1984; 4(1):28-46. PubMed ID: 6329988 [TBL] [Abstract][Full Text] [Related]
5. Differences in cytotoxic effects of activated murine peritoneal macrophages and J774 monocytic cells on metastatic variants of B16 melanoma. Miner KM; Klostergaard J; Granger GA; Nicolson GL J Natl Cancer Inst; 1983 Apr; 70(4):717-24. PubMed ID: 6339778 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of experimental metastasis and extracellular matrix degradation by butanol extracts from B16-F1 murine melanoma. Keren Z; Leland F; Nakajima M; LeGrue SJ Cancer Res; 1989 Jan; 49(2):295-300. PubMed ID: 2910449 [TBL] [Abstract][Full Text] [Related]
7. Tumor cell and host properties affecting the implantation and survival of blood-borne metastatic variants of B16 melanoma. Fidler IJ; Nicolson GL Isr J Med Sci; 1978 Jan; 14(1):38-50. PubMed ID: 632082 [TBL] [Abstract][Full Text] [Related]
8. Mechanism of tumor cell resistance to lysis by syngeneic lymphocytes. Fidler IJ; Bucana C Cancer Res; 1977 Nov; 37(11):3945-56. PubMed ID: 908034 [TBL] [Abstract][Full Text] [Related]
9. Effects of the immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma. Kalland T Cancer Res; 1986 Jun; 46(6):3018-22. PubMed ID: 3486041 [TBL] [Abstract][Full Text] [Related]
10. Effects of tunicamycin on B16 metastatic melanoma cell surface glycoproteins and blood-borne arrest and survival properties. Irimura T; Gonzalez R; Nicolson GL Cancer Res; 1981 Sep; 41(9 Pt 1):3411-8. PubMed ID: 7260906 [TBL] [Abstract][Full Text] [Related]
11. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases. Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L Cancer Res; 1995 Nov; 55(21):4941-9. PubMed ID: 7585534 [TBL] [Abstract][Full Text] [Related]
12. Correlation of the production of plasminogen activator with tumor metastasis in B16 mouse melanoma cell lines. Wang BS; McLoughlin GA; Richie JP; Mannick JA Cancer Res; 1980 Feb; 40(2):288-92. PubMed ID: 7356511 [TBL] [Abstract][Full Text] [Related]
13. Characterization in vivo and in vitro of tumor cells selected for resistance to syngeneic lymphocyte-mediated cytotoxicity. Fidler IJ; Gersten DM; Budmen MB Cancer Res; 1976 Sep; 36(9 pt.1):3160-5. PubMed ID: 975082 [TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of metastases with lymphocytes treated with exogenous RNA in mice bearing B16 melanoma. Watanabe MA; Almeida DO; Serrano SV; Sales VS; Soares FA; de Lucca FL Cell Mol Biol (Noisy-le-grand); 1997 May; 43(3):393-8. PubMed ID: 9193794 [TBL] [Abstract][Full Text] [Related]
15. Serologically detectable MHC and tumor-associated antigens on B16 melanoma variants and humoral immunity in mice bearing these tumors. Baniyash M; Smorodinsky NI; Yaakubovicz M; Witz IP J Immunol; 1982 Sep; 129(3):1318-23. PubMed ID: 7108209 [TBL] [Abstract][Full Text] [Related]
16. Reduced tumorigenicity of B16-F10 mouse melanoma cells transfected with mycobacterial antigen 85A. Tarrant JP; Walsh MJ; Blanchard MC; Lee TD; Hoskin DW; Giacomantonio CA Int J Oncol; 2004 Dec; 25(6):1693-9. PubMed ID: 15547707 [TBL] [Abstract][Full Text] [Related]
17. Growth inhibition of established B16-F10 lung metastases by sequential aerosol delivery of p53 gene and 9-nitrocamptothecin. Gautam A; Waldrep JC; Densmore CL; Koshkina N; Melton S; Roberts L; Gilbert B; Knight V Gene Ther; 2002 Mar; 9(5):353-7. PubMed ID: 11938455 [TBL] [Abstract][Full Text] [Related]
18. Relationship between cellular procoagulant activity and metastatic capacity of B16 mouse melanoma variants. Gilbert LC; Gordon SG Cancer Res; 1983 Feb; 43(2):536-40. PubMed ID: 6848176 [TBL] [Abstract][Full Text] [Related]
19. Differential extraction of tumor-specific transplantation antigen and embryonic antigen from simian virus 40- and adenovirus 7-induced sarcoma cells of hamsters with 1-butanol and 3 M potassium chloride. Coggin JH; Gillis LD; Payne WJ J Natl Cancer Inst; 1984 Apr; 72(4):853-62. PubMed ID: 6323810 [TBL] [Abstract][Full Text] [Related]
20. [Immunogenicity of 2 murine B16 melanoma variants with high metastatic potential]. Hosni M; Santini R; Deschaux P; Pacheco H C R Seances Soc Biol Fil; 1990; 184(1):47-54. PubMed ID: 2150781 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]